Company Overview
Autolus Therapeutics (AUTL) is a clinical-stage biotechnology company developing next-generation Chimeric Antigen Receptor (“CAR”) T cell therapies for the treatment of both hematological cancers and solid tumors. Using their broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active CAR Ts that are designed better to recognize cancer cells.
While approved CAR Ts such as Kymirah from Novartis (NVS) and Yescarta from Gilead Sciences (GILD) have shown high remission rates in hematological cancers, many patients eventually relapse within